Closing The Readiness Gap For CGTs In Community-Based Care

Cell and gene therapies hold the promise of durable, even curative outcomes for patients with serious genetic and cellular diseases. Yet access remains strikingly limited: only one in five eligible patients ultimately receives treatment, according to McKinsey. That gap is not primarily a scientific problem. It reflects the structural reality that most CGT administration today is concentrated in academic medical centers, which offer the specialized infrastructure and staffing these therapies require but cannot serve the full eligible population at scale.

Expanding into community-based care settings is the logical next step, but it is not a straightforward one. Community hospitals face real challenges in building the operational readiness CGTs demand, from staff training and patient identification to care coordination and reimbursement navigation. Closing the readiness gap means understanding where those barriers are greatest and which interventions move the needle on access.

Assess your current community engagement strategy against these barriers to identify where targeted investment will have the greatest impact on patient reach.